middle.news
How Will Rhythm’s NATA Accreditation Boost ColoSTAT®’s Cancer Test Launch?
9:25am on Tuesday 24th of June, 2025 AEST
•
Healthcare
Read Story
How Will Rhythm’s NATA Accreditation Boost ColoSTAT®’s Cancer Test Launch?
9:25am on Tuesday 24th of June, 2025 AEST
Key Points
NATA accreditation reinstated for geneType laboratory
Integration of Genetype assets completed post-acquisition
Enables ColoSTAT® deployment as an in-house in vitro diagnostic
Supports clinical rollout and real-world data collection
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Rhythm Biosciences (ASX:RHY)
OPEN ARTICLE